Association of two BRM promoter polymorphisms and smoking status with malignant pleural mesothelioma risk and prognosis

Brahma (BRM), of the SWI/SNF complex, has two 6 to 7 bp insertion promoter polymorphisms (BRM-741/BRM-1321) that cause epigenetic BRM suppression, and are associated with risk of multiple cancers. BRM polymorphisms were genotyped in malignant pleural mesothelioma (MPM) cases and asbestos-exposed controls. Multivariable logistic regression (risk) and Cox regression (prognosis) were performed, including stratified analyses by smoking status to investigate the effect of polymorphisms on MPM risk and prognosis. Although there was no significant association overall between BRM-741/BRM-1321 and risk in patients with MPM, a differential effect by smoking status was observed (P-interaction < .001), where homozygous variants were protective (aOR of 0.18-0.28) in ever smokers, while never smokers had increased risk when carrying homozygous variants (aOR of 2.7-4.4). While there was no association between BRM polymorphisms and OS in ever-smokers, the aHR of carrying homozygous-variants of BRM-741, BRM-1321 or both were 4.0 to 8.6 in never-smokers when compared to wild-type carriers. Mechanistically, lower mRNA expression of BRM was associated with poorer general cancer prognosis. Electrophoretic mobility shift assays and chromatin immunoprecipitation experiments (ChIP) revealed high BRM insertion variant homology to MEF2 regulatory binding sites. ChIP experimentation confirmed MEF2 binding only occurs in the presence of insertion variants. DNA-affinity purification assays revealed YWHA scaffold proteins as vital to BRM mRNA expression. Never-smokers who carry BRM homozygous variants have an increased chance of developing MPM, which results in worse prognosis. In contrast, in ever-smokers, there may be a protective effect, with no difference in overall survival. Mechanisms for the interaction between BRM and smoking require further study.

[1]  T. Chan,et al.  Tobacco Smoking-Associated Alterations in the Immune Microenvironment of Squamous Cell Carcinomas , 2018, Journal of the National Cancer Institute.

[2]  J. Hoeijmakers,et al.  DNA damage sensitivity of SWI/SNF-deficient cells depends on TFIIH subunit p62/GTF2H1 , 2018, Nature Communications.

[3]  P. Parfrey,et al.  Two functional indel polymorphisms in the promoter region of the Brahma gene (BRM) and disease risk and progression-free survival in colorectal cancer , 2018, PloS one.

[4]  R. Weinberg,et al.  Understanding the tumor immune microenvironment (TIME) for effective therapy , 2018, Nature Medicine.

[5]  S. Albelda,et al.  Novel therapies for malignant pleural mesothelioma. , 2018, The Lancet. Oncology.

[6]  Geoffrey Liu,et al.  Two BRM promoter polymorphisms predict poor survival in patients with hepatocellular carcinoma , 2018, Molecular carcinogenesis.

[7]  G. Matullo,et al.  Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma. , 2017, Cancer letters.

[8]  V. Dolžan,et al.  Matrix Metalloproteinases Polymorphisms as Prognostic Biomarkers in Malignant Pleural Mesothelioma , 2017, Disease markers.

[9]  A. Azad,et al.  Association of BRM promoter polymorphisms and esophageal adenocarcinoma outcome , 2017, Oncotarget.

[10]  S. Gallinger,et al.  BRM polymorphisms, pancreatic cancer risk and survival , 2016, International journal of cancer.

[11]  Bingshu E. Chen,et al.  BRM Promoter Polymorphisms and Survival of Advanced Non–Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial , 2016, Clinical Cancer Research.

[12]  G. Scagliotti,et al.  BRCA1‐Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  J. Leigh,et al.  Malignant mesothelioma in Australia 2015: Current incidence and asbestos exposure trends , 2016, Journal of toxicology and environmental health. Part B, Critical reviews.

[14]  D. Saranath,et al.  Gene polymorphisms and oral cancer risk in tobacco habitués , 2016, Tumor Biology.

[15]  S. Pastorino,et al.  Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma , 2016, Oncogene.

[16]  B. Qian,et al.  DNA Repair Gene Polymorphisms in Relation to Non-Small Cell Lung Cancer Survival , 2015, Cellular Physiology and Biochemistry.

[17]  C. Toon,et al.  Loss of expression of BAP1 predicts longer survival in mesothelioma , 2015, Pathology.

[18]  D. Reisman,et al.  Flavonoids from each of the six structural groups reactivate BRM, a possible cofactor for the anticancer effects of flavonoids. , 2014, Carcinogenesis.

[19]  D. Reisman,et al.  The silencing of the SWI/SNF subunit and anticancer gene BRM in Rhabdoid tumors , 2014, Oncotarget.

[20]  J. Soh,et al.  Hereditary Lung Cancer Syndrome Targets Never Smokers with Germline EGFR Gene T790M Mutations , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  M. Tsao,et al.  Two BRM promoter insertion polymorphisms increase the risk of early-stage upper aerodigestive tract cancers , 2014, Cancer medicine.

[22]  D. Reisman,et al.  Identifying targets for the restoration and reactivation of BRM , 2014, Oncogene.

[23]  R. Gilbert,et al.  Association of two BRM promoter polymorphisms with head and neck squamous cell carcinoma risk. , 2013, Carcinogenesis.

[24]  Benjamin M. Robinson,et al.  Malignant pleural mesothelioma: an epidemiological perspective. , 2012, Annals of cardiothoracic surgery.

[25]  M. Spitz,et al.  Predictors of Survival in Never-Smokers with Non–Small Cell Lung Cancer: A Large-Scale, Two-Phase Genetic Study , 2012, Clinical Cancer Research.

[26]  M. Ladanyi,et al.  Clinical Characteristics of Patients with Malignant Pleural Mesothelioma Harboring Somatic BAP1 Mutations , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[27]  N. Cox,et al.  Germline BAP1 mutations predispose to malignant mesothelioma , 2011, Nature Genetics.

[28]  M. Tsao,et al.  Two novel BRM insertion promoter sequence variants are associated with loss of BRM expression and lung cancer risk , 2011, Oncogene.

[29]  D. Reisman,et al.  Pharmacologic reversal of epigenetic silencing of the anticancer protein BRM: a novel targeted treatment strategy , 2011, Oncogene.

[30]  J. Mcdonald.  Epidemiology of malignant mesothelioma--an outline. , 2010, The Annals of occupational hygiene.

[31]  M. Esteller,et al.  Epigenetic modifications and human disease , 2010, Nature Biotechnology.

[32]  Yuh-Shan Jou,et al.  ATM polymorphisms and risk of lung cancer among never smokers. , 2010, Lung cancer.

[33]  D. Reisman,et al.  The SWI/SNF complex and cancer , 2009, Oncogene.

[34]  H. Nagatsuka,et al.  Loss of Heterozygosity at the 9p21–24 Region and Identification of BRM as a Candidate Tumor Suppressor Gene in Head and Neck Squamous Cell Carcinoma , 2009, Cancer investigation.

[35]  W. Gerald,et al.  The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer. , 2008, Cancer research.

[36]  S. Wacholder,et al.  Gene Expression Signature of Cigarette Smoking and Its Role in Lung Adenocarcinoma Development and Survival , 2008, PloS one.

[37]  Shuji Fujita,et al.  Frequent loss of Brm expression in gastric cancer correlates with histologic features and differentiation state. , 2007, Cancer research.

[38]  D. Reisman,et al.  The reversible epigenetic silencing of BRM: implications for clinical targeted therapy , 2007, Oncogene.

[39]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[40]  Taiji Ito,et al.  The Brm gene suppressed at the post-transcriptional level in various human cell lines is inducible by transient HDAC inhibitor treatment, which exhibits antioncogenic potential , 2005, Oncogene.

[41]  M. Yaniv,et al.  SWI/SNF chromatin-remodeling factors induce changes in DNA methylation to promote transcriptional activation. , 2005, Cancer research.

[42]  K. Buetow,et al.  Chromatin Remodeling Factors and BRM/BRG1 Expression as Prognostic Indicators in Non-Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[43]  W. Tan,et al.  A functional polymorphism in the SULT1A1 gene (G638A) is associated with risk of lung cancer in relation to tobacco smoking. , 2003, Carcinogenesis.

[44]  M. Gerber,et al.  Interactions between genetic polymorphism of cytochrome P450‐1B1, sulfotransferase 1A1, catechol‐o‐methyltransferase and tobacco exposure in breast cancer risk , 2003, International journal of cancer.

[45]  H. Jarrett,et al.  Affinity purification of DNA-binding proteins. , 2001, Journal of biochemical and biophysical methods.

[46]  Tae-Hee Han,et al.  14-3-3 associates with and activates the MEF2D transcription factor during muscle cell differentiation , 2001, Nucleic Acids Res..

[47]  M. Yaniv,et al.  When the SWI/SNF complex remodels … the cell cycle , 2001, Oncogene.

[48]  Weidong Wang,et al.  Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies , 2001, Journal of cellular physiology.

[49]  J. Herndon,et al.  Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. , 1998, Chest.

[50]  L. Chodosh,et al.  Purification of DNA‐Binding Proteins Using Biotin/Streptavidin Affinity Systems , 1996, Current protocols in protein science.

[51]  Guha,et al.  Functional interactions between the hBRM/hBRG1 transcriptional activators and the pRB family of proteins , 1996, Molecular and cellular biology.

[52]  J. Fickett.  Copyright � 1996, American Society for Microbiology Quantitative Discrimination of MEF2 Sites , 1995 .

[53]  G. May,et al.  An EMSA-based method for determining the molecular weight of a protein--DNA complex. , 1993, Nucleic acids research.

[54]  E. Wynder,et al.  Cigarette smoking, asbestos exposure, and malignant mesothelioma. , 1991, Cancer research.

[55]  J. Peto,et al.  Mesothelioma mortality in asbestos workers: implications for models of carcinogenesis and risk assessment. , 1982, British Journal of Cancer.

[56]  Hong Ping Chen,et al.  Histone deacetylases and mechanisms of regulation of gene expression. , 2015, Critical reviews in oncogenesis.

[57]  H. Pass,et al.  Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. , 2015, Carcinogenesis.

[58]  H. Popper,et al.  BAP1 Protein is a Progression Factor in Malignant Pleural Mesothelioma , 2013, Pathology & Oncology Research.

[59]  Michael F. Smith,et al.  Electrophoretic Mobility Shift Assay (EMSA). , 2001, Methods in molecular medicine.

[60]  G. Giaccone,et al.  Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.